Bayer Schering Pharma AG: PharmaVitae Profile now available at ReportsandReports
Dallas, TX: ReportsandReports announce Bayer Schering Pharma AG: PharmaVitae Profile Market Research Report in its Store.
Browse complete Report at : http://www.reportsandreports.com/reports/8203-bayer-schering-pharma-ag-pharmavitae-profile.html
This analysis examines the historical and forecast performance for Bayer Schering in the prescription pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information
Reasons to Purchase
• Benchmark Bayer Schering Pharma’s performance against key rivals in the ethical pharmaceutical sector
• Analyse how Bayer’s acquisition of Schering AG in 2006 has notably enhanced the company’s HealthCare division
• Assess how an increased healthcare focus and merger-related synergies will drive an increase in operating profit
• Table Of Contents
• ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
• Chapter 1 About this profile 3
• PharmaVitae Explorer database 3
Chapter structure 3
Executive summary 3
Quarterly update 3
Company introduction 3
Company sales 4
Company financials 4
Key products 4
Data sourcing 4
Sales data 4
Analyst consensus 4
• Chapter 2 Executive summary 5
• Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2003-15 6
Financial performance, 2003-15 7
Bayer Schering Pharma: PharmaVitae forecasts at a glance 8
Strategic insight 9
Bayer’s diversified structure is unusual within Big Pharma peer set 9
Weak revenue performance initiates restructuring strategy in 2003 9
Bayer’s restructuring efforts have proved successful to date 10
Bayer’s portfolio to drive prescription pharma growth over 2009-15 11
SWOT analysis 12
Strengths 12
Weaknesses 13
Opportunities 13
Threats 15
Table of Contents 16
Table of figures 18
• Chapter 3 Quarterly news update 19
• Latest quarterly sales 19
Latest comment 19
Q1 2010 19
Q4 2009 19
FIGO 2009: Bayer-Schering maintains leadership in contraception 19
Q3 2009 21
Q2 2009 21
Latest prescription pharma product news 22
Q1 2010 22
Q4 2009 22
Q3 2009 23
Q2 2009 25
Latest corporate news 26
Q1 2010 26
Q4 2009 27
Q3 2009 27
Q2 2009 27
Future product milestones 29
• Chapter 4 Company introduction 31
• Key findings 31
Background 32
Key corporate developments 32
Current corporate structure 33
Bayer Healthcare 33
Bayer MaterialScience 33
Bayer CropScience 34
Bayer Healthcare business unit structure 35
Bayer Schering Pharma 35
Prescription pharmaceuticals 35
Diagnostic imaging 35
Consumer Care 35
Animal Health 36
Medical Care 36
Medrad 36
Diabetes Care 36
M&A history 37
Acquisition of Roche Consumer Health AG (RCH) 37
Lanxess AG Spin-off 37
Divestment of US Plasma Products 38
Acquisition of Schering AG 38
Recent M&A promotes Bayer’s healthcare focus 38
Divestment of Diagnostics Division 38
Divestment of H.C. Starck and Wolff Walsrode 39
Acquisition of Possis Medical and Sagmel Inc 39
M&A strategy 39
• Chapter 5 Company sales 41
• Key findings 41
Prescription pharmaceutical sales and growth rate analysis, 2003-15 42
Product analysis 45
Product analysis, 2003-09 46
Product analysis, 2009-15 49
Therapy area analysis 53
Geographic analysis 56
Launch/core/expiry analysis 59
Explanation of launch/core/expiry analysis 59
Launch analysis, 2009-15 60
Core analysis, 2009-15 62
Expiry analysis, 2009-15 64
Launch/core/expiry configuration, 2009-15 66
Molecule type analysis 67
Externalization analysis 70
• Chapter 6 Company financials 73
• Key findings 73
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003-09 74
Operating costs and profit analysis 76
Operating costs and profit analysis, 2003-09 77
Operating cost ratio and profit margin analysis, 2003-09 79
Operating cost ratio and profit margin analysis, 2009-15 81
Operating costs and profit analysis, 2009-15 82
• Chapter 7 Key products 83
• Key findings 83
Overview 84
Xarelto 85
Overview 85
Sales forecast 86
A replacement for Warfarin? 86
Pradaxa is direct competitior 87
Nexavar 88
Overview 88
Sales forecast 89
Nexavar encounters strong competition in the RCC market 89
HCC market to offer better sales potential 89
Further indication broadening will boost sales growth 90
Mirena 91
Overview 91
Sales forecast 92
An alternative to sterilization 92
Key competitors 92
riociguat 94
Overview 94
Sales forecast 95
alpharadin 96
Overview 96
Sales forecast 97
Bayer co-development agreement with Algeta grants access to Alpharadin 97
Complementary nature indicates potential for combination therapy 97
Betaferon 98
Overview 98
Sales forecast 99
Betaferon: a success story despite initial challenges 99
Novartis agreement 99
Key competitors 100
Yaz 102
Overview 102
Sales forecast 103
The Impact of Yasmin’s invalidated patent protection 103
New market launches 103
Ciprobay/Cipro 105
Overview 105
Sales forecast 106
Yasmin 107
Overview 107
Sales forecast 108
Yasmin: a historical growth driver 108
Yasmin patent invalidated following challenge from Barr Pharmaceuticals 108
The impact of generics 109
Key competitors 109
• Chapter 8 Appendix 111
• References 111
Abbreviations 111
Exchange rates 113
About Datamonitor 114
About Datamonitor Healthcare 114
Datamonitor consulting 114
Disclaimer 116
ABBREVIATIONS
Browse all : Healthcare Market Research Reports
http://www.reportsandreports.com/cat/healthcare-market-research.html
Browse all : Datamonitor Market Research Reports
http://www.reportsandreports.com/Publisher/datamonitor-market-research.html-market-research.html
Browse all Newly Published Market Research Reports
http://www.reportsandreports.com/LatestReport.aspx
Related Reports:
Browse all: Bayer Schering Pharma AG-Deals & Alliances Report
at : http://www.reportsandreports.com/reports/31645-bayer-schering-pharma-ag-deals-alliances-report.html
Browse all: Bayer Schering Pharma AG-Detailed Product Pipeline
at : http://www.reportsandreports.com/reports/29159-bayer-schering-pharma-ag-detailed-product-pipeline.html
Browse all : Bayer Schering Pharma AG-Company Report
http://www.reportsandreports.com/reports/4801-bayer-schering-pharma-ag-company-report.html
Browse all : Bayer Schering Pharma AG – SWOT Analysis
http://www.reportsandreports.com/reports/2060-bayer-schering-pharma-ag-swot-analysis.html
Browse all : Schering-Plough Corporation: PharmaVitae Profile
http://www.reportsandreports.com/reports/8053-schering-plough-corporation-pharmavitae-profile.html
About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/
